MLTX — MoonLake Immunotherapeutics

Nasdaq · Health Care · Pharmaceuticals · CIK 1821586 ·
Last close
$20.36
Market Cap
$1.70B
52W High
$23.29
52W Low
$15.76
ADV30
1,288,605
Next earnings
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -70,024,000 -69,707,000 400,374,000 298,490,000 146,350,000
Dec 2025 0 -65,218,000 -62,427,000 424,433,000 334,517,000 119,952,000
Sep 2025 0 -71,434,000 -69,729,000 414,335,000 350,736,000 123,144,000
Jun 2025 0 -60,698,000 -55,220,000 460,096,000 306,681,000 102,152,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-224,153,000
Investing CF
$146,844,000
Financing CF
$103,519,000
CapEx
$-342,567
Dividends Paid
Buybacks
$0
EPS Diluted TTM
$-3.58
As of
2026-06-07

Balance + Analyst (yfinance extras)

Retained Earnings
$-532,618,000
Inventory
Receivables
$5,763,000
ST Investments
$59,431,000
EBIT TTM
$-248,892,000
Pretax Income TTM
$-258,390,000
Interest Exp TTM
$9,498,000
Analysts
13

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -244,834,000 -227,318,000 424,433,000 119,952,000 -196,007,000
Dec 2024 0 -143,091,000 -118,936,000 477,933,000 24,542,000 -116,587,000
Dec 2023 0 -54,123,000 -36,007,000 526,540,115 13,049,096 -42,778,000
Dec 2022 0 -65,061,417 -49,973,249 76,843,301 8,076,603 -55,893,900

TTM Snapshot

Revenues TTM
$-141,718,488
NetIncome TTM
$-55,278,174
OpCashFlow TTM
$0
Assets (Latest)
$477,933,000
Forward EPS
$-3.43

Max Pain — expiry 2026-07-17

max pain strike: $20.00 · spot: $20.36 · call oi: 4,940 · put oi: 2,394
Expected Move to 2026-07-17: ±$2.42 (11.91%) — implied range $17.94$22.79 · ATM straddle on $20.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
MPLT MapLight Therapeutics, Inc. $1.68B $39.32
DMRA Damora Therapeutics, Inc. $1.76B $28.53
INVA Innoviva, Inc. $1.64B $22.24
BHC Bausch Health Companies Inc. $1.79B $4.78
SEPN Septerna, Inc. $1.62B $35.93

News headlines (Yahoo Finance, 1h cache)

MoonLake Immunotherapeutics' CFO Sells 39K Shares
2026-07-03 14:34 · Yahoo
MoonLake Immunotherapeutics (MLTX) Outlook Strengthens as Analysts See Major Opportunity in Hidradenitis Suppurativa
2026-06-30 13:22 · Yahoo
How Investors May Respond To MoonLake Immunotherapeutics (MLTX) VELA Data And Upsized Follow-On Offering
2026-06-25 12:07 · Yahoo
Why MoonLake Immunotherapeutics Stock Wilted on Wednesday
2026-06-25 00:09 · Yahoo
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Amid Easing US-Iran Tensions
2026-06-24 13:17 · Yahoo
MLTX Stock Extends Pullback After Biggest Rally In Over 6 Months Following Skin Disease Trial Data — A Look At The Latest Development
2026-06-24 11:48 · Yahoo
MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering
2026-06-24 03:08 · Yahoo
MLTX Stock Clocks Best Day In Over 6 Months — What’s Driving The Investor Optimism?
2026-06-22 20:59 · Yahoo
MoonLake Immunotherapeutics Announces Proposed Public Offering
2026-06-22 20:01 · Yahoo
Why Is MLTX Stock Rallying Nearly 20% Overnight?
2026-06-22 00:52 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.